$0.51
Eyenovia is a biotechnology business based in the US. Eyenovia shares (EYEN) are listed on the NASDAQ and all prices are listed in US Dollars. Eyenovia employs 57 staff and has a trailing 12-month revenue of around $31,405.
Our top picks for where to buy Eyenovia stock
How to buy Eyenovia stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – EYEN. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Eyenovia stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Eyenovia stock price (NASDAQ: EYEN)
Use our graph to track the performance of EYEN stocks over time.Eyenovia shares at a glance
Latest market close | $0.51 |
---|---|
52-week range | $0.37 - $2.57 |
50-day moving average | $0.90 |
200-day moving average | $1.21 |
Wall St. target price | $10.83 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.78 |
Is it a good time to buy Eyenovia stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Eyenovia price performance over time
Historical closes compared with the close of $0.5128 from 2024-09-05
1 week (2024-08-30) | -6.78% |
---|---|
1 month (2024-08-06) | -44.92% |
3 months (2024-06-06) | -34.26% |
6 months (2024-03-06) | -69.75% |
1 year (2023-09-06) | -72.58% |
---|---|
2 years (2022-09-06) | -73.70% |
3 years (2021-09-03) | 5.24 |
5 years (2019-09-06) | 3.41 |
Eyenovia financials
Revenue TTM | $31,405 |
---|---|
Gross profit TTM | $12.4 million |
Return on assets TTM | -92.94% |
Return on equity TTM | -914.66% |
Profit margin | 0% |
Book value | $-0.04 |
Market Capitalization | $42.3 million |
TTM: trailing 12 months
Eyenovia share dividends
We're not expecting Eyenovia to pay a dividend over the next 12 months.
Eyenovia share price volatility
Over the last 12 months, Eyenovia's shares have ranged in value from as little as $0.37 up to $2.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eyenovia's is 1.777. This would suggest that Eyenovia's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Eyenovia overview
Eyenovia, Inc. , a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics. It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired, and clobetasol propionate ophthalmic suspension for the treatment of post-operative pain and inflammation following ocular surgery. The company is also developing the Optejet delivery system for use in combination with its drug-device therapeutic programs and for out-licensing for use in combination with therapeutics for additional indications. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co. , Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi.
Frequently asked questions
nullWhat percentage of Eyenovia is owned by insiders or institutions?
Currently 13.31% of Eyenovia shares are held by insiders and 15.26% by institutions. How many people work for Eyenovia?
Latest data suggests 57 work at Eyenovia. When does the fiscal year end for Eyenovia?
Eyenovia's fiscal year ends in December. Where is Eyenovia based?
Eyenovia's address is: 295 Madison Avenue, New York, NY, United States, 10017 What is Eyenovia's ISIN number?
Eyenovia's international securities identification number is: US30234E1047 What is Eyenovia's CUSIP number?
Eyenovia's Committee on Uniform Securities Identification Procedures number is: 30234E104
More guides on Finder
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
7 best day trading platforms of 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for beginners: 11 best trading platforms to get started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 best international stock brokers to invest in foreign assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 best discount brokers of 2024 for low-cost trading and investing
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
10 best stock apps of 2024 to elevate your mobile trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 best brokerage accounts for buying stocks, options and more in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question